Kopran Ltd
NSE:KOPRAN

Watchlist Manager
Kopran Ltd Logo
Kopran Ltd
NSE:KOPRAN
Watchlist
Price: 154.41 INR 4.51% Market Closed
Market Cap: 7.5B INR
Section:
 

Relative Value

The Relative Value of one KOPRAN stock under the Base Case scenario is 204.2 INR. Compared to the current market price of 154.41 INR, Kopran Ltd is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KOPRAN Relative Value
Base Case
204.2 INR
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.3
P/S
P/S
Price to Sales
1.3
vs History
82
vs Industry
63
Median 3Y
1.6
Median 5Y
1.7
Industry
2.6
More Details
42.4
P/E
P/E
Price to Earnings
42.4
vs History
4
vs Industry
25
Median 3Y
25.6
Median 5Y
21.5
Industry
21.4
More Details
8.7
P/OCF
P/OCF
Price to OCF
8.7
vs History
74
vs Industry
15
Median 3Y
21.5
Median 5Y
18.3
Industry
16.4
More Details
17.2
P/FCFE
P/FCFE
Price to FCFE
17.2
vs History
57
vs Industry
0
Median 3Y
18.5
Median 5Y
31.3
Industry
22.8
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
90
vs Industry
41
Median 3Y
1.9
Median 5Y
2.3
Industry
2.2
More Details
1.5
EV/S
EV/S
Enterprise Value to Sales
1.5
vs History
79
vs Industry
62
Median 3Y
1.7
Median 5Y
1.7
Industry
2.9
More Details
4.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.3
vs History
74
vs Industry
48
Median 3Y
5.1
Median 5Y
5.1
Industry
5.5
More Details
16.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.3
vs History
34
vs Industry
28
Median 3Y
15
Median 5Y
14.2
Industry
13
More Details
23.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.2
vs History
19
vs Industry
27
Median 3Y
18.6
Median 5Y
17.6
Industry
16.5
More Details
10.4
EV/OCF
EV/OCF
Enterprise Value to OCF
10.4
vs History
76
vs Industry
15
Median 3Y
23.8
Median 5Y
19.1
Industry
15.6
More Details
49.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
49.6
vs History
14
vs Industry
3
Median 3Y
-35.6
Median 5Y
-17.8
Industry
18.7
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
93
vs Industry
45
Median 3Y
1.6
Median 5Y
1.9
Industry
1.9
More Details

Multiples Across Competitors

KOPRAN Competitors Multiples
Kopran Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Kopran Ltd
NSE:KOPRAN
7.5B INR 1.3 42.4 16.3 23.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
266.1B CHF 4.3 28.2 12 14
UK
AstraZeneca PLC
LSE:AZN
218.6B GBP 5.1 31.4 108.7 159
CH
Novartis AG
SIX:NOVN
216.6B CHF 4.9 18.9 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.5 10.8 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Kopran Ltd
NSE:KOPRAN
Average P/E: 26.6
42.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.5
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Kopran Ltd
NSE:KOPRAN
Average EV/EBITDA: 401.4
16.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Kopran Ltd
NSE:KOPRAN
Average EV/EBIT: 1 714.4
23.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
KOPRAN intrinsic value, competitors valuation, and company profile.
DCF Valuation
KOPRAN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KOPRAN stock valuation using valuation multiples.
Wall Street Estimates
KOPRAN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KOPRAN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.